Pacira BioSciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pacira BioSciences (PCRX).

Price Target Range — 11 Quarters

Analyst Consensus — 11 Analysts

8Buy

2Hold

1Sell

Consensus RatingBuy# Analysts11Avg. Consensus PT$33Upside to Avg. PT+33.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$32
Sep 9, 2026	Leerink Partners	Daniel Clark	Initiate	Market Perform	$28
Aug 5, 2026	RBC Capital	Douglas Miehm	PT Raise	Sector Perform	$24→$25
Aug 5, 2026	Needham	Serge Belanger	PT Raise	Buy	$32→$33
Jul 1, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$38
May 1, 2026	RBC Capital	Douglas Miehm	PT Raise	Sector Perform	$22→$24
May 1, 2026	Needham	Serge Belanger	PT Raise	Buy	$30→$32
Mar 26, 2026	Barclays	Glen Santangelo	PT Cut	Equal-Weight	$27→$25
Jan 9, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$38
Jan 9, 2026	Needham	Serge Belanger	Maintained	Buy	$30
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Equal-Weight	$27
Nov 17, 2025	HC Wainwright & Co.	Douglas Tsao	Assumes	Buy	$38
Nov 7, 2025	Truist Securities	Les Sulewski	PT Cut	Buy	$30→$28
May 9, 2025	Needham	Serge Belanger	PT Cut	Buy	$32→$30
Apr 8, 2025	Needham	Serge Belanger	Maintained	Buy	$32
Apr 8, 2025	HC Wainwright & Co.	Oren Livnat	PT Raise	Buy	$48→$65
Feb 28, 2025	Barclays	Balaji Prasad	PT Raise	Overweight	$17→$24
Feb 28, 2025	Needham	Serge Belanger	PT Raise	Buy	$30→$32
Feb 28, 2025	HC Wainwright & Co.	Oren Livnat	PT Raise	Buy	$57→$70
Jan 30, 2025	Truist Securities	Les Sulewski	Upgrade	Sell→Hold	$8→$25

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target of $32

Oppenheimer analyst Les Sulewski initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Outperform rating and announces Price Target of $32.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Pacira BioSciences with Market Perform Rating, Announces Price Target of $28

Leerink Partners analyst Daniel Clark initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Market Perform rating and announces Price Target of $28.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $25

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $24 to $25.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $33

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $32 to $33.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintains $38 price target.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $24

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $22 to $24.

Benzinga Newsdesk

Pacira BioSciences Inc

Pacira BioSciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target of $32

PRO
Leerink Partners Initiates Coverage On Pacira BioSciences with Market Perform Rating, Announces Price Target of $28

PRO
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $25

PRO
Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $33

PRO
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target

PRO
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $24

People Also Watch

People Also Watch

Pacira BioSciences Inc

Pacira BioSciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROOppenheimer Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target of $32

PROLeerink Partners Initiates Coverage On Pacira BioSciences with Market Perform Rating, Announces Price Target of $28

PRORBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $25

PRONeedham Maintains Buy on Pacira BioSciences, Raises Price Target to $33

PROHC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target

PRORBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $24

People Also Watch

People Also Watch

PRO
Oppenheimer Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target of $32

PRO
Leerink Partners Initiates Coverage On Pacira BioSciences with Market Perform Rating, Announces Price Target of $28

PRO
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $25

PRO
Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $33

PRO
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target

PRO
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $24